NASDAQ:QTTB
Q32 Bio Inc. Stock News
$14.77
-0.610 (-3.97%)
At Close: Jun 25, 2024
Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
06:59am, Thursday, 09'th May 2024
-- Completed enrollment in bempikibart alopecia areata (AA) Phase 2 clinical trial, with topline results expected in Q4'24; enrollment in bempikibart atopic dermatitis (AD) Phase 2 clinical trial rema
Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer
07:00am, Wednesday, 03'rd Apr 2024
WALTHAM, Mass. , April 3, 2024 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasi
Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
04:15pm, Monday, 25'th Mar 2024
-- Q32 Bio to focus on advancement of bempikibart (ADX-914) in ongoing atopic dermatitis (AD) and alopecia areata (AA) Phase 2 clinical trials and commencement of ADX-097 Phase 2 renal basket clinica
